Although blood monitoring using serum CEA and CA19‐9 has been conventionally introduced for the managements of patients with gastric cancer, serum levels of conventional blood markers do not necessarily coincide with tumor behavior.9 Therefore, surrogate blood markers are needed clinically to monitor tumor aggressiveness in real time. Here, CEACAM5 is linked to neoplasm.